Skip to content
drillr.ai

NVCR

NovoCure Limited

NASDAQ · JEHealthcareMedical - Instruments & Supplies
$15.94+0.13%

Price as of Jul 20, 2026

NVCR news

NovoCure Limited news

A server-rendered, paginated timeline of the latest available company news.

  1. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 19, 2026 / Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ:NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NovoCure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for in

    ACCESSWIRE ·

  2. NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm

    NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm The Schall Law Firm (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54557255&newsitemid=20260620892484&lan=en-US&anchor=The+Schall+Law+Firm&index=1&md5=be586ba1b489dc3225573ebfaf62f350) , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NA

    Business Wire ·

  3. NovoCure Limited (NVCR) Securities Fraud Investigation - Levi & Korsinsky

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June 18, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into NovoCure Limited ("NovoCure Limited") (NASDAQ:NVCR) concerning potential violations of the federal securities laws. On its Q3 2025 earnings call, then-CEO Ashley Cordova indicated TRIDENT was examining "the benefit of starting Tumor Treating Fields concurrently with chemo radiation in newly diagnosed GBM," as opposed to the current pr

    ACCESSWIRE ·

  4. Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)

    Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) PR Newswire NEW YORK,, June 18, 2026 Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday on June 18, 2026. NEW YORK,, June 18, 2026 /PRNewswire/ -- Investors who held Novocure Limited (NASDAQ: NVCR) shares lost more than $3 per

    PR Newswire ·

  5. Novocure to Participate in 2026 Leerink Global Healthcare Conference

    Novocure to Participate in 2026 Leerink Global Healthcare Conference Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 11:20 a.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor

    Business Wire ·

  6. Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 25, 2026 /PRNewswire/ -- Equity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Nov

    PR Newswire ·